Lung Cancer Chemotherapy, New Treatment and Related Patents

Author(s): Attapon Cheepsattayakorn, Ruangrong Cheepsattayakorn

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 9 , Issue 3 , 2014

Become EABM
Become Reviewer


The majority of patients with lung cancer present with advanced stage which contributes to death of more people than any other malignancy in the world. The discovery of a number of lung cancer-molecular alterations contributes to uniquely targeted therapies with specific inhibitors for non-small cell lung cancer such as erlotinib, gefitinib and crizotinib. Pemetrexed has statistically shown significantly reduced adverse side effects of drug compared with docetaxel. V1801, an analog of gefitinib may overcome gefitinib resistance in patients with non-small cell lung cancer. Thymosin α1, an immunomodulator significantly improves patient’s quality of life by enhancing T-cell function, stimulation of Tcell maturation and differentiation. Various novel compounds and chemotherapeutics were introduced in 2013 patents such as taxane, quinazoline, arylamino purine, benzodiazepine, pyrrolopyrimidine, nitrobenzamide, cyclopropane amide, 4-iodo-3-nitrobenzamide, heteroaryl (alkyl) dithiocarbamate, and histone deacetylase in treating non-small-cell lung cancer and piperidine, piperazine, picoplatin, and arsenic trioxide in treating small-cell lung cancer.

Keywords: Cancer, chemotherapy, lung, lung cancer-molecular alterations, related patents, treatment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [372 - 381]
Pages: 10
DOI: 10.2174/1574892809666140520120806
Price: $65

Article Metrics

PDF: 43